Compounds > estrone
Page last updated: 2024-11-07

estrone and Impotence

estrone has been researched along with Impotence in 3 studies

Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19902 (66.67)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Spitzer, M1
Bhasin, S1
Travison, TG1
Davda, MN1
Stroh, H1
Basaria, S1
Krese, A1
Teter, J1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Androgen Modulation of Response to Selective Phosphodiesterase Inhibitors in Erectile Dysfunction[NCT00512707]Phase 4140 participants (Actual)Interventional2006-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Derogatis Affects Balance Scale (DABS)

The Derogatis Affects Balance Scale (DABS) is a 40-item mood inventory and consists of 4 positive affect dimensions (joy, contentment, vigor, and affection) as well as 4 negative affect dimensions(anxiety, depression, guilt, and hostility). Each domain was calculated as the sum of 5-items and could range from 0 to 20, wherein higher scores indicate greater affectivity. (NCT00512707)
Timeframe: Week 0, Week 8, Week 14

,
Interventionunits on a scale (Mean)
Joy at week 0Joy at week 8Joy at week 14Contentment at week 0Contentment at week 8Contentment at week 14Vigor at week 0Vigor at week 8Vigor at week 14Affection at week 0Affection at week 8Affection at week 14Depression at week 0Depression at week 8Depression at week 14Anxiety at week 0Anxiety at week 8Anxiety at week 14Guilt at week 0Guilt at week 8Guilt at week 14Hostility at week 0Hostility at week 8Hostility at week 14
Placebo13.113.512.713.213.712.812.013.012.614.614.714.53.94.34.15.55.65.84.14.53.74.34.64.4
Testosterone12.713.113.212.813.413.311.812.512.613.914.214.24.14.14.24.95.14.93.43.73.84.74.64.7

Change From Baseline in Erectile Function Domain Score of the International Index of Erectile Function (IIEF)

IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with Erectile Function domain range of 1 to 30 with higher scores representing better function. (NCT00512707)
Timeframe: Week 0, week 8, week 11, week 14

,
Interventionunits on a scale (Mean)
Erectile function at week 0Erectile function at week 8Erectile function at week 11Erectile function at week 14
Placebo20.121.320.119.8
Testosterone19.621.322.521.7

Change From Baseline in Free Testosterone

Free testosterone levels were calculated from total testosterone at screening and equilibrium dialysis at randomization and at trial end. (NCT00512707)
Timeframe: Week 0, Week 14

,
Interventionpg/mL (Mean)
Free Testosterone at week 0Free Testosterone at week 14
Placebo101103
Testosterone110239

Change From Baseline in Marital Interaction Scale of CAncer Rehabilitation Evaluation System-Short Form (CARES-SF)

CAncer Rehabilitation Evaluation System-short form (CARES-SF) marital interaction scale consists of 6 items (range from 0 (best) to 4) and mean of these 6 questions was used to determine intimacy and partner interaction. Lower CARES-SF scores correspond with improved marital interaction. (NCT00512707)
Timeframe: Week 0, Week 8, Week 14

,
Interventionunits on a scale (Mean)
CARES-SF: Marital relationship at week 0CARES-SF: Marital relationship at week 8CARES-SF: Marital relationship at week 14
Placebo0.740.790.79
Testosterone0.790.860.81

Change From Baseline in Men's Sexual Health Questionnaire (MSHQ)

MSHQ, a 25-item questionnaire, assesses sexual function and satisfaction. It consists 5 domains: Erection (3 items, ranging from 0 to 15 (best)), Ejaculation (7 items, ranging from 1 to 35 (best)), Satisfaction (6 items, ranging from 6 to 30 (best)), Sexual desire (4 items, ranging 4-20 (best)), and Sexual activity (3 items, ranging 3-15 (best)). A composite score is the sum of Ejaculation and Satisfaction domains, ranging from 7 to 65 (best), with higher score representing better sexual function and satisfaction. (NCT00512707)
Timeframe: Week 0, Week 8, Week 14

,
Interventionunits on a scale (Mean)
Erectile at week 0Erectile at week 8Erectile at week 14Ejaculation at week 0Ejaculation at week 8Ejaculation at week 14Sexual satisfaction at week 0Sexual satisfaction at week 8Sexual satisfaction at week 14Sexual desire at week 0Sexual desire at week 8Sexual desire at week 14Sexual activity at week 0Sexual activity at week 8Sexual activity at week 14Composite MSHQ at week 0Composite MSHQ at week 8Composite MSHQ at week 14
Placebo5.96.97.226.127.826.921.622.421.510.310.710.16.76.96.547.750.248.5
Testosterone5.36.36.926.828.328.422.122.322.59.910.510.57.07.17.048.850.651.1

Change From Baseline in Other Domains of International Index of Erectile Function (IIEF)

IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function. (NCT00512707)
Timeframe: Week 0, week 8, week 11, week 14

,
Interventionunits on a scale (Mean)
Orgasmic function at week 0Orgasmic function at week 8Orgasmic function at week 11Orgasmic function at week 14Sexual desire at week 0Sexual desire at week 8Sexual desire at week 11Sexual desire at week 14Intercourse satisfaction at week 0Intercourse satisfaction at week 8Intercourse satisfaction at week 11Intercourse satisfaction at week 14Overall satisfaction at week 0Overall satisfaction at week 8Overall satisfaction at week 11Overall satisfaction at week 14Composite IIEF at week 0Composite IIEF at week 8Composite IIEF at week 11Composite IIEF at week 14
Placebo7.07.87.47.46.77.06.86.89.49.89.58.86.67.37.07.050535150
Testosterone7.07.67.97.96.57.07.17.09.510.110.610.06.46.87.46.747535653

Change From Baseline in Positive Affects Ratio (PAR) of Derogatis Affects Balance Scale (DABS)

The Derogatis Affects Balance Scale (DABS) is a 40-item mood inventory and consists of 4 positive affect dimensions (joy, contentment, vigor, and affection) as well as 4 negative affect dimensions(anxiety, depression, guilt, and hostility). Positive Affects Ratio (PAR), ranging from 0 to 1, is the proportion of total scores (sum of all 8 domains) that is positive (sum of 4 positive domains). Higher PAR represents better affectivity. (NCT00512707)
Timeframe: Week 0, Week 8, Week 14

,
Interventionratios (Mean)
Positive Affect Ratio at week 0Positive Affect Ratio at week 8Positive Affect Ratio at week 14
Placebo0.760.770.76
Testosterone0.750.760.78

Change From Baseline in Psychological General Well-Being Index Score (PGWBI)

Well-being and mood were assessed using the Psychological General Well-Being Index (PGWBI), a 22-item questionnaire that evaluated six dimensions of self-reported wellness: Anxiety (5 questions), Depressed Mood (3 questions), Positive Well-Being (4 questions), Self Control (3 questions), General Health (3 questions), and Vitality (4 questions). Higher scores in each dimension reflect increasing well-being. A global score (ranging from 0 (poor QoL) to 110 (good QoL)) was calculated as the sum of each domain score. The global score and those of its 6 dimensions were normalized to a 100% scale to facilitate comparison. (NCT00512707)
Timeframe: Week 0, Week 8, Week 14

,
Interventionunits on a scale (Mean)
Positive Well-being at week 0Positive Well-being at week 8Positive Well-being at week 14Depressed Mood at week 0Depressed Mood at week 8Depressed Mood at week 14General Health at week 0General Health at week 8General Health at week 14Anxiety at week 0Anxiety at week 8Anxiety at week 14Self Control at week 0Self Control at week 8Self Control at week 14Vitality at week 0Vitality at week 8Vitality at week 14Global Score at week 0Global Score at week 8Global Score at week 14
Placebo636360868683747570767672848684686967747572
Testosterone606564868585727372767677868687666869737575

Change From Baseline in Quality of Life Specific to Male Erection Difficulties (QOL-MED)

The Quality of Life for men with Erection Difficulties (QOL-MED) is a cross-cultural instrument to measure quality of life specific to male erection difficulties. The 18 items for this scale were generated from interviews with men with erection difficulties by TH Wagner in 1996. Higher QOL-MED scores reflect better quality of life. Scores were standardized to range of 0 to 100. (NCT00512707)
Timeframe: Week 0, Week 8, Week 14

,
Interventionunits on a scale (Mean)
QOL-MED scale at week 0QOL-MED scale at week 8QOL-MED scale at week 14
Placebo627069
Testosterone566566

Change From Baseline in Sex Hormone Binding Globulin (SHBG)

(NCT00512707)
Timeframe: Week 0, Week 14

,
Interventionnmol/L (Mean)
SHBG at week 0SHBG at week 14
Placebo27.528
Testosterone32.232

Change From Baseline in Sexual Encounter Profile (SEP)

Sexual Encounter Profile (SEP) diaries were used to assess frequency of sexual activity, sildenafil use, vaginal penetration, completion of intercourse with ejaculation, and overall satisfaction with sexual encounters. Minimum value is 0 with no maximum limit, wherein higher values representing better sexual encounter. (NCT00512707)
Timeframe: Week 0, week 8, week 14

,
Interventionevents/week (Mean)
Sexual Encounter Attempts at week 0Sexual Encounter Attempts at week 8Sexual Encounter Attempts at week 14Vaginal Penetration at week 0Vaginal Penetration at week 8Vaginal Penetration at week 14Ejaculation at week 0Ejaculation at week 8Ejaculation at week 14Overall Satisfied with Sexual Encounters at week0Overall Satisfied with Sexual Encounters at week8Overall Satisfied with Sexual Encounters at wk 14
Placebo3.03.03.02.62.72.62.22.52.31.92.32.5
Testosterone2.82.83.32.72.42.72.12.32.62.02.22.8

Change From Baseline in Successful Sexual Intercourse of Sexual Encounter Profile (SEP)

Sexual Encounter Profile (SEP) diaries were used to assess frequency of sexual activity, sildenafil use, vaginal penetration, completion of intercourse with ejaculation, and overall satisfaction with sexual encounters. Higher percentage of Ejaculations or Satisfaction in successful sexual intercourse represents better sexual function. (NCT00512707)
Timeframe: Week 0, week 8, week 14

,
Interventionpercentage of sexual intercourses (Mean)
Successful Sexual Intercourse (Ejaculations) wk0Successful Sexual Intercourse (Ejaculations) wk8Successful Sexual Intercourse (Ejaculations)wk14Successful Sexual Intercourse (Satisfaction) wk0Successful Sexual Intercourse (Satisfaction) wk8Successful Sexual Intercourse (Satisfaction)wk14
Placebo748479677583
Testosterone767880697683

Change From Baseline in Total Testosterone

Total testosterone levels were measured between 7:30 and 10:10 a.m. using a liquid chromatography-tandem mass spectrometry assay certified by the Centers for Disease Control and Prevention's Hormone Standardization Program. (NCT00512707)
Timeframe: Week 0, Week 14

,
Interventionng/dL (Mean)
Total Testosterone at week 0Total Testosterone at week 14
Placebo347339
Testosterone364649

Trials

1 trial available for estrone and Impotence

ArticleYear
Sildenafil increases serum testosterone levels by a direct action on the testes.
    Andrology, 2013, Volume: 1, Issue:6

    Topics: Adult; Aged; Androstenedione; Dihydrotestosterone; Erectile Dysfunction; Estradiol; Estrone; Humans;

2013

Other Studies

2 other studies available for estrone and Impotence

ArticleYear
[Steroid spectrum of diabetic men in relationship to their potency].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1966, Oct-01, Volume: 21, Issue:19

    Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Androsterone; Cortisone; Dehydroepiandrosterone;

1966
Treatment of endocrine impotence.
    British medical journal, 1972, Oct-14, Volume: 4, Issue:5832

    Topics: Aged; Erectile Dysfunction; Estradiol; Estrogens; Estrone; Humans; Male; Testosterone

1972